

1 **Advancing our understanding of skeletal muscle across the lifecourse: protocol for the**

2 **MASS_Lifecourse study and characteristics of the first 80 participants**

3

4 **Authors and affiliations**

Initials	Surname	Qualification	Affiliations
R M	Dodds	PhD	1,2
C	Hurst	PhD	1,2
S J	Hillman	MSc	1,2
K	Davies	PhD	1
T J	Aspray	MD	1,2
A	Granic	PhD	1,2
A A	Sayer*	PhD	1,2

5

6 1. AGE Research Group, Newcastle University Institute for Translational and Clinical
7 Research, Newcastle upon Tyne, UK

8 2. NIHR Newcastle Biomedical Research Centre, Newcastle University and Newcastle upon
9 Tyne NHS Foundation Trust, Newcastle upon Tyne, UK

10 * Corresponding author:

11 Email: avan.sayer@newcastle.ac.uk

12 Address: NIHR Newcastle Biomedical Research Centre, 3rd Floor Biomedical Research

13 Building, Campus for Ageing and Vitality, Newcastle upon Tyne NE4 5PL, United Kingdom.

14 Tel: +44 (0)191 208 1148.

1 **Abstract**

2 Introduction

3 Sarcopenia, the age-related loss of skeletal muscle strength and mass, carries a significant
4 burden for affected individuals. There has been little investigation of sarcopenia using
5 experimental medicine techniques to study human muscle tissue in detail. The aim of the
6 Muscle Ageing Sarcopenia Studies Lifecourse (MASS_Lifecourse) study is to recruit up to
7 160 participants, equally divided between females and males between ages 45 and 85 years
8 for detailed phenotyping of skeletal muscle health. Here we describe the protocol for the
9 study and the characteristics of the first 80 participants.

10 Methods

11 We are recruiting participants from three sources in the north-east of England. Study
12 fieldwork comprises a home visit (or videocall) for consent and assessment of health,
13 cognition, lifestyle, and wellbeing. This is followed by a visit to a clinical research facility for
14 assessment of sarcopenia status and collection of samples including a vastus lateralis muscle
15 biopsy. We produced descriptive statistics for the first 80 participants, including expressing
16 their grip strength relative to normative data in the form of Z-scores.

17 Results

18 The first 80 participants (53.8% female) covered the target ages, ranging from 48 to 84 years.
19 They were regularly physically active, reported good physical function and had a prevalence
20 sarcopenia (including probable sarcopenia) of 11.3% based on the revised European
21 consensus. Their grip strength was similar to that in the general population, with a mean Z-
22 score of 0.09 standard deviations (95% CI: -1.64, 1.83) above that expected.

1 Conclusions

- 2 The MASS_Lifecourse study combines comprehensive health and lifestyle data with a range
3 of biological samples including skeletal muscle. The findings from planned analyses should
4 contribute to improvements in the diagnosis, treatment, and prevention of sarcopenia.

1 **Introduction**

2 Sarcopenia is the loss of muscle strength and mass as we age. It refers specifically to the
3 situation where a person's muscle strength, from tests such as grip strength and five chair
4 stand time, and mass, from measurements such as a dual-energy X-ray absorptiometry (DXA)
5 scanning, are below standard cut-points [1]. The importance of muscle strength and mass is
6 highlighted by the strong evidence that people with lower results for these tests are at greater
7 risk of disability [2], use of social and health care including hospitalisation [3,4] and even all-
8 cause mortality rates [5].

9
10 There is therefore growing clinical interest in sarcopenia and its potential treatments [6]. A
11 range of mechanisms for sarcopenia have been investigated including mitochondrial
12 dysfunction, anabolic resistance, cellular senescence, motor unit remodelling and oxidative
13 stress [7]. However to date there has been comparatively little investigation of sarcopenia
14 using recent experimental medicine techniques such as the use of 'omics' to study human
15 muscle tissue in detail [8].

16 The prevalence of sarcopenia increases with age, with around one-quarter of those aged 85
17 found to be affected in data from the Newcastle 85+ Study [9]. By this age, it is more likely
18 that sarcopenia will be accompanied by other ageing syndromes such as disability and frailty.
19 This may limit our ability to establish whether changes seen in muscle are due to sarcopenia,
20 as they may reflect both sarcopenia and its associated conditions.

21
22 An alternative approach is to explore mechanisms of skeletal muscle ageing in the period
23 spanning both mid-life and old age, defined in this study as ages 45-85 years. This will
24 provide opportunities to better understand risk factors and to be able to implement
25 interventions at an earlier stage, analogous to the screening in mid-life that is now established

1 for cardiovascular disease risk [10]. An added benefit of recruiting people in this age group
2 for detailed assessment of skeletal muscle is that participants who may be eligible for
3 sarcopenia trials can be quickly identified [11].
4
5 We have previously carried out two pilot Muscle Ageing Sarcopenia Studies (MASS) of
6 detailed muscle phenotyping (MASS_Pilot [12] and MASS_PD [13]), and we have built on
7 this experience to design the MASS_Lifecourse study. The overall aim of the
8 MASS_Lifecourse study is to recruit a sample of up to 160 participants, divided between
9 women and men between ages 45 and 85 years for detailed phenotyping of skeletal muscle
10 health. In the present paper we describe (i) the protocol for the MASS_Lifecourse study and
11 (ii) the characteristics of the first 80 participants.

1 **Methods**

2 Recruitment

3 We recruited participants from the north-east of England from three different sources. These
4 were: primary care (local GP practices acting as patient identification centres within the
5 North East and North Cumbria Clinical Research Network), secondary care (clinics run
6 within the Newcastle upon Tyne Hospitals NHS Foundation Trust), and the NIHR
7 Bioresource Centre Newcastle (a large panel of individuals who have expressed an interest in
8 taking part in research studies). We started the fieldwork in October 2018, with suspension
9 between March 2020 and September 2020 due to the COVID-19 pandemic.

10

11 *Inclusion and exclusion criteria*

12 The inclusion criteria were being aged between 45 and 85 years and having capacity to
13 consent to take part. The exclusion criteria were taking anticoagulant or antiplatelet
14 medications (except for aspirin for primary prevention of cardiovascular disease which could
15 be suspended), diabetes mellitus, immunosuppressant medication, and pregnancy. We also
16 excluded individuals where biopsy of the vastus lateralis muscle was judged not to be feasible
17 by a clinician in the team. Prompts for further assessment by a clinician include a body mass
18 index (BMI) in the obese range, significant mobility limitation or conspicuous superficial
19 veins at the biopsy site. We assessed these criteria throughout the recruitment process to
20 identify at an early stage if a person was not eligible to take part.

21

22 *Ethical approval and informed consent*

23 The study was approved by the North East – Newcastle & North Tyneside 1 Research Ethics
24 Committee. We obtained informed consent from all participants, including asking if they
25 gave permission for biological samples to be used in future collaboration with partners

1 outside the UK and those in the commercial sector. Consent was rechecked before each part
2 of the study.

3

4 Study fieldwork

5 The study fieldwork comprised (1) consideration of inclusion and exclusion criteria (as
6 above); (2) assessment of health, cognition, lifestyle and wellbeing, carried out either in the
7 participant's home or via videocall (with the latter introduced following the COVID-19
8 pandemic); followed by a visit to CARU (our Clinical Ageing Research Unit: a clinical
9 research facility) for (3) identification of sarcopenia status and other clinical measurements
10 and (4) collection of skeletal muscle and other samples. A summary of the fieldwork
11 components is given in Table 1 and full details are provided below.

12

13 *Assessment of health, cognition, lifestyle and wellbeing*

14 We collected information on health status, including long-term conditions, regular
15 medications, hospital admissions and contact with health and social care professionals. We
16 assessed cognition using the standardized mini-mental state examination (SMMSE) [14] and
17 Montreal cognitive assessment (MoCA) [15]. We assessed smoking history, alcohol intake,
18 and diet using a 20-item food frequency questionnaire [16]. We characterised habitual
19 physical activity in two ways: firstly, using the rapid assessment of physical activity (RAPA)
20 questionnaire [17] and secondly with seven-day accelerometry using a GENEActiv®
21 Original physical activity monitor (ActivInsights Ltd, Cambridge, UK) worn on the dominant
22 wrist at a measurement frequency of 100 Hz.

23

24 We asked participants about their educational history (years spent in school and in higher
25 education), home and car ownership, and their own and (if relevant) their partner's main

1 occupation classified using the Office for National Statistics (ONS) simplified NS-SEC
2 analytic class [18]. We assessed quality of life using the Short Form 36 (SF-36) questionnaire
3 [19] and mood using the Geriatric Depression Score [20].

4

5 *Assessment of sarcopenia status and other clinical measurements*

6 We assessed sarcopenia status using measures recommended in the revised European
7 consensus on the definition and diagnosis of sarcopenia [1]. We assessed self-reported
8 physical function using the SARC-F questionnaire [21]. We measured grip strength (kg) by
9 taking three assessments from each hand using a Jamar dynamometer, with the maximum
10 value used in analyses [22]. We recorded the time take to complete five chair stands [23]. We
11 tested physical performance by measuring normal gait speed over 4 metres and tests of
12 standing balance. We assessed appendicular lean mass using segmental bioimpedance using a
13 Tanita MC-780MA body composition analyser (Tanita Corporation, Arlington Heights, IL,
14 USA), and using DXA (Lunar iDXA, GE Healthcare, USA). Other clinical measurements
15 included height, weight, hip and waist circumference, and lying and standing blood pressure.

16

17 *Collection of skeletal muscle and other samples*

18 Participants collected a stool sample at home using the OMNIgene GUT kit (DNA Genotek,
19 Ottawa, Canada) and brought this with them. Once in CARU we collected blood samples
20 after an overnight fast, used to perform a set of routine clinical tests, as well as to provide
21 stored blood for subsequent DNA and RNA extraction and aliquots of serum and plasma.
22 After participants had breakfast, we asked them to provide a urine sample for subsequent
23 metabolomic analyses. At approximately 11am on the day of the CARU visit we performed a
24 biopsy of the vastus lateralis muscle, usually taken on the right side, and using a Weil-
25 Blakesley conchotome [24]. We aimed to collect three muscle samples, with one placed

1 immediately into RNAlater solution (RNAlater™ stabilization solution, Thermofisher
2 Scientific). The other two were placed in gauze prior to processing: one sample orientated
3 and mounted for histology, and then both samples flash frozen in isopentane cooled in liquid
4 nitrogen prior to storage at -80°C [25]. We observed the participant for around two hours
5 following the biopsy procedure and followed-up by telephone the next day and a week later.

6

7 Data management

8 We stored participants' details in a password-protected database on a secure network drive,
9 accessible only by members of the study team with the required approvals in place. We used
10 a pseudonymised participant identifier throughout the fieldwork. We used double data entry
11 when inputting data from paper forms. We carried out checks for values outside of the
12 feasible range, and we checked the consistency when information was combined from
13 different sources (for example, checking that a participant's weight recorded during a DXA
14 scan was consistent with that from bioimpedance analysis).

15

16 Maintenance of cohort

17 At the end of the fieldwork, we sought participants' consent to keep them updated on
18 progress with the study and we send an annual newsletter for this purpose. We also sought
19 their permission to contact them about further studies that might be of interest; to date, this
20 has included attending for magnetic resonance imaging of skeletal muscle to assess motor
21 unit function [26].

22

23 Statistical analyses in this paper

24 In the present paper, we describe the characteristics of the first 80 participants, based on a
25 selection of the variables described under study fieldwork, above, and as shown in Table 2.

1 From the GeneActiv physical activity monitor recordings we calculated the mean daily
2 duration of moderate to vigorous physical activity (MVPA) using the library GGIR [27],
3 defined as periods for which measured acceleration was greater than 0.1g calculated using the
4 Euclidean norm minus one algorithm, and sustained for at least 80% of a minimum bout of 5
5 minutes.

6
7 We used the cut-points recommended in the revised European consensus guidelines for
8 diagnosis and severity of sarcopenia [1], classifying participants as having probable
9 sarcopenia (weak grip strength [< 27 kg in males and < 16 kg in females] and/or prolonged
10 time for five chair stands [> 15 seconds]), confirmed sarcopenia if they additionally had low
11 values for appendicular lean mass index (ALMI, appendicular lean mass in kg divided by
12 height-squared [< 7.0 kg/m² in males and < 5.5 kg/m² in females]), and severe sarcopenia if
13 they also had slow gait speed (≤ 0.8 m/s). We also compared our grip strength values to
14 published British normative data [28], by expressing each patient's value as a Z-score. Each
15 Z-score is calculated as the patient's grip strength value less the mean expected for their age
16 and sex, divided by the grip strength standard deviation (SD) for their age and sex. Z-scores
17 of +1 and -1 indicate grip strength values one standard deviation above and below,
18 respectively, that expected for age and sex.

19
20 We produced descriptive statistics stratified by sex, with differences between males and
21 females analysed using chi-squared tests in the case of categorical variables, and Wilcoxon
22 rank sum tests for continuous variables. We carried out statistical analysis using R, version
23 4.0.4 [29].

1 **Results**

2 Here we describe characteristics of the first 80 participants in the MASS_Lifecourse Study
3 who had a home visit and attended the CARU, as shown in Table 2. The participants spanned
4 the intended age range (minimum 48, maximum 84 and median 64 years), with an
5 approximately even split between males (46.2%) and females (53.8%). During this period of
6 fieldwork, we also visited seven potential participants at home and found that they had
7 exclusion criteria that prevented them from taking part. A further five participants had a
8 home visit and were recruited to the study but did not progress to the CARU visit due to a
9 change in their personal circumstances.

10

11 Assessment of health, cognition, lifestyle and wellbeing

12 The majority (n=45, 56.3%) of participants had two or more long-term condition (i.e. they
13 had multimorbidity), with a tendency for females to have more long-term conditions than
14 males, as shown in Table 2. Participants had normal cognition based on the MoCA test. In
15 terms of lifestyle, most participants undertook regular aerobic activity based on the RAPA1
16 questionnaire, and in keeping with this had evidence of regular moderate-vigorous physical
17 activity based on GENEActiv accelerometry. Most participants did not undertake regular
18 strength and flexibility training as assessed using the RAPA2 questionnaire. Finally, most
19 participants had high self-rated physical function based on the SF-36 questionnaire,
20 especially so in males.

21

22 Assessment of sarcopenia status and other clinical measurements

23 Most participants did not score any points on the SARC-F questionnaire (n=66, 82.5%) or
24 meet the criteria for the European revised sarcopenia definition, with (n=9, 11.2%) having
25 probable sarcopenia or greater, as shown in Table 2. As expected, we saw stronger average

- 1 grip strength and ALMI in males compared to females. Participants' grip strength Z-score
- 2 values were typically as expected for their age and sex, with a mean Z-score of 0.09 standard
- 3 deviations (95% CI: -1.64, 1.83) above population reference values. Finally, most participants
- 4 had a BMI in the overweight range.

1 **Discussion**

2 Summary of findings

3 We have successfully established a cohort study that will improve our understanding of
4 changes in skeletal muscle in mid-life and old age, with fieldwork ongoing at the time of
5 writing. The assessments as described in this protocol paper include a comprehensive
6 assessment of a range of health and lifestyle factors, cognition, and sarcopenia status. There
7 is also collection of a range of biological samples including skeletal muscle ready for
8 subsequent analyses including multi-omics. The first 80 participants covered the intended age
9 range (45 to 85 years) and were characterised by having regular physical activity, good self-
10 reported physical function, and low levels of sarcopenia.

11

12 Interpretation of findings

13 We had a high rate of those who underwent a home visit going on to have assessments in the
14 CARU (87%) as we used initial telephone contact to check exclusion criteria and to check
15 that it was a feasible time to take part in the study. We anticipated a healthy volunteer effect
16 and there was some evidence that the first 80 participants in MASS_Lifecourse were, on
17 average, more active and had better self-reported physical function than the general
18 population. In contrast, we saw levels of muscle strength (assessed by grip strength) which
19 were at the same level as that seen in the general population, and few participants reported
20 undertaking regular strength training.

21

22 Strengths and limitations

23 A strength of our work is that we used the same recruitment sources to cover the age range
24 from 45 – 85 years, meaning that any age-related differences in muscle characteristics will
25 not have arisen owing to the use of different recruitment strategies in different age groups.

1 There was some evidence of a healthy volunteer effect, and this may have contributed to the
2 low levels of confirmed (or severe) sarcopenia present in the study. This also has the potential
3 to be a strength of this cohort, since it provides an opportunity to gain insights into the
4 biological processes that lead to sarcopenia, and also to understand age-related changes in
5 skeletal muscle (sometimes termed primary sarcopenia) separated as far as possible from
6 muscle changes due to long-term conditions, termed secondary sarcopenia, and an area of
7 growing research interest [1,31].

8

9 Plans for future research

10 A range of analyses are planned, due to take place following the completion of study
11 fieldwork in 2022 to avoid batch effects. This includes histology, transcriptomics, and
12 proteomics of skeletal muscle. These will complement existing studies in this area but with a
13 larger sample size than available previously [32]. This study protocol also forms a template
14 for future cohort studies, including in people living with specific conditions, or clusters of
15 long-term conditions. The use of such a standardised approach will allow the comparison of
16 findings with data from the present study.

17

18 Conclusions

19 We have successfully established a cohort study to improve our understanding of changes in
20 skeletal muscle in mid-life and old age. The planned analyses of the samples collected in the
21 MASS_Lifecourse study and their relation to a range of participant characteristics will
22 considerably increase our understanding of the biological mechanisms underpinning age-
23 related muscle loss. This knowledge should in turn lead to improvements in our ability to
24 diagnose, treat and prevent sarcopenia.

1 **Declaration of sources of funding**

2 AAS is Director of the NIHR Newcastle Biomedical Research Centre.

3

4 The research was supported by the National Institute for Health Research (NIHR) Newcastle

5 Biomedical Research Centre based at Newcastle upon Tyne Hospitals NHS Foundation Trust

6 and Newcastle University. The views expressed are those of the author(s) and not necessarily

7 those of the NHS, the NIHR or the Department of Health.

1 **References**

- 2 1. Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruyere O, Cederholm T, *et al.* Sarcopenia:
3 revised European consensus on definition and diagnosis. *Age Ageing*. 2019;48(1):16–31.
- 4 2. den Ouden MEM, Schuurmans MJ, Arts IEMA, van der Schouw YT. Physical
5 performance characteristics related to disability in older persons: a systematic review.
6 *Maturitas*. 2011;69(3):208–19.
- 7 3. Janssen I, Shepard DS, Katzmarzyk PT, Roubenoff R. The healthcare costs of sarcopenia
8 in the United States. *J. Am. Geriatr. Soc.* 2004;52(1):80–5.
- 9 4. Simmonds SJ, Syddall HE, Walsh B, Evandrou M, Dennison EM, Cooper C, *et al.*
10 Understanding NHS hospital admissions in England: linkage of Hospital Episode Statistics to
11 the Hertfordshire Cohort Study. *Age Ageing*. 2014;43(5):653–60.
- 12 5. Cooper R, Kuh D, Hardy R, Mortality Review Group. Objectively measured physical
13 capability levels and mortality: systematic review and meta-analysis. *BMJ*. 2010;341:c4467.
- 14 6. Cruz-Jentoft AJ, Sayer AA. Sarcopenia. *Lancet*. 2019;393(10191):2636–46.
- 15 7. Aihie Sayer A, Robinson SM, Patel HP, Shavlakadze T, Cooper C, Grounds MD. New
16 horizons in the pathogenesis, diagnosis and management of sarcopenia. *Age Ageing*.
17 2013;42(2):145–50.
- 18 8. Morley JE, Anker SD. Myopenia and precision (P4) medicine. *J. Cachexia. Sarcopenia*
19 *Muscle*. 2017.
- 20 9. Dodds RM, Granic A, Davies K, Kirkwood TBL, Jagger C, Sayer AA. Prevalence and
21 incidence of sarcopenia in the very old: findings from the Newcastle 85+ Study. *J Cachexia*
22 *Sarcopenia Muscle*. 2017;8(2):229–37.
- 23 10. Robson J, Dostal I, Sheikh A, Eldridge S, Madurasinghe V, Griffiths C, *et al.* The NHS
24 Health Check in England: an evaluation of the first 4 years. *BMJ Open*. 2016;6:e008840.
- 25 11. Band MM, Sumukadas D, Struthers AD, Avenell A, Donnan PT, Kemp PR, *et al.*
26 Leucine and ACE inhibitors as therapies for sarcopenia (LACE trial): study protocol for a
27 randomised controlled trial. *Trials*. 2018;19(1):6.
- 28 12. Dodds RM, Davies K, Granic A, Hollingsworth KG, Warren C, Gorman G.
29 Mitochondrial respiratory chain function and content are preserved in the skeletal muscle of
30 active very old men and women. *Exp. Gerontol*. 2018;113:80–85.
- 31 13. Yarnall AJ, Granic A, Waite S, Hollingsworth KG, Warren C, Vincent AE, *et al.* The
32 feasibility of muscle mitochondrial respiratory chain phenotyping across the cognitive
33 spectrum in Parkinson’s disease. *Exp. Gerontol*. 2020;138:110997.
- 34 14. Molloy DW, Standish TIM. A Guide to the Standardized Mini-Mental State Examination.
35 *Int. Psychogeriatrics*. 1997;9(S1):87–94.
- 36 15. Nasreddine ZS, Phillips NA, Bédirian V, Charbonneau S, Whitehead V, Collin I, *et al.*
37 The Montreal Cognitive Assessment, MoCA: A Brief Screening Tool For Mild Cognitive
38 Impairment. *J. Am. Geriatr. Soc.* 2005;53(4):695–699.

- 1 16. Topolski TD, LoGerfo J, Patrick DL, Williams B, Walwick J, Patrick MB. The Rapid
2 Assessment of Physical Activity (RAPA) among older adults. *Prev. Chronic Dis.*
3 2006;3(4):1–8.
- 4 17. Office of National Statistics. ONS Occupation Coding Tool. 2021. Available at:
5 [https://onsdigital.github.io/dp-classification-tools/standard-occupational-](https://onsdigital.github.io/dp-classification-tools/standard-occupational-classification/ONS_SOC_occupation_coding_tool.html)
6 [classification/ONS_SOC_occupation_coding_tool.html](https://onsdigital.github.io/dp-classification-tools/standard-occupational-classification/ONS_SOC_occupation_coding_tool.html) . Accessed September 2, 2021.
- 7 18. Ware JE, Gandek B. Overview of the SF-36 Health Survey and the International Quality
8 of Life Assessment (IQOLA) Project. *J. Clin. Epidemiol.* 1998;51(11):903–912.
- 9 19. Yesavage JA, Brink TL, Rose TL, Lum O, Huang V, Adey M, *et al.* Development and
10 validation of a geriatric depression screening scale: a preliminary report. *J. Psychiatr. Res.*
11 17(1):37–49.
- 12 20. Malmstrom TK, Miller DK, Simonsick EM, Ferrucci L, Morley JE. SARC-F: A symptom
13 score to predict persons with sarcopenia at risk for poor functional outcomes. *J. Cachexia.*
14 *Sarcopenia Muscle.* 2016;7(1):28–36.
- 15 21. Roberts HC, Denison HJ, Martin HJ, Patel HP, Syddall H, Cooper C, *et al.* A review of
16 the measurement of grip strength in clinical and epidemiological studies: towards a
17 standardised approach. *Age Ageing.* 2011;40(4):423–9.
- 18 22. Dodds RM, Murray JC, Granic A, Hurst C, Uwimpuhwe G, Richardson S, *et al.*
19 Prevalence and factors associated with poor performance in the 5-chair stand test: findings
20 from the Cognitive Function and Ageing Study II and proposed Newcastle protocol for use in
21 the assessment of sarcopenia. *J. Cachexia. Sarcopenia Muscle.* 2021;12(2):308–318.
- 22 23. Baczynska AM, Shaw S, Roberts HC, Cooper C, Sayer AA, Patel HP. Human Vastus
23 Lateralis Skeletal Muscle Biopsy Using the Weil-Blakesley Conchotome. *JoVE J. Vis. Exp.*
24 2016;(March):e53075, doi:10.3791/53075.
- 25 24. Meng H, Janssen PML, Grange RW, Yang L, Beggs AH, Swanson LC, *et al.* Tissue
26 triage and freezing for models of skeletal muscle disease. *J Vis. Exp.* 2014;89.
- 27 25. Tullo E, Dodds RM, Birkbeck M, Habiballa L, Sayer AA. Paving the translational ageing
28 research pathway—training the next generation of researchers. *Age Ageing.* 2020:1–4.
- 29 26. van Hees VT, Fang Z, Zhao JH, Heywood J, Mirkes E, Sabia S, *et al.* {GGIR}: Raw
30 Accelerometer Data Analysis. 2021.
- 31 27. Dodds RM, Syddall HE, Cooper R, Benzeval M, Deary IJ, Dennison EM, *et al.* Grip
32 strength across the life course: normative data from twelve British studies. *PLoS One.*
33 2014;9(12):e113637.
- 34 28. R Core Team. R: A Language and Environment for Statistical Computing. R Foundation
35 for Statistical Computing, Vienna, Austria. URL <http://www.R-project.org/>. 2021.
- 36 29. St-Jean-Pelletier F, Pion CH, Leduc-Gaudet J-P, Sgarioto N, Zovilé I, Barbat-Artigas S,
37 *et al.* The impact of ageing, physical activity, and pre-frailty on skeletal muscle phenotype,
38 mitochondrial content, and intramyocellular lipids in men. *J. Cachexia. Sarcopenia Muscle.*
39 2017;8(2):213–228.
- 40 30. Dodds RM, Granic A, Robinson SM, Sayer AA. Sarcopenia, long-term conditions, and

- 1 multimorbidity: findings from UK Biobank participants. *J. Cachexia. Sarcopenia Muscle.*
- 2 2020;11:62–8.

- 3 31. Tumasian RA, Harish A, Kundu G, Yang JH, Ubaida-Mohien C, Gonzalez-Freire M, *et*
- 4 *al.* Skeletal muscle transcriptome in healthy aging. *Nat. Commun.* 2021;12(1).

1 **Table 1: Overview of study fieldwork**

Component	Location	Components
Initial contact to discuss study	Telephone	<ul style="list-style-type: none"> • Opportunity to raise questions after reading study participant information sheet • Assessment of inclusion and exclusion criteria
Assessment of health, cognition, lifestyle and wellbeing	Own home*	<ul style="list-style-type: none"> • Long-term conditions and medications • SMMSE and MoCA • Food frequency questionnaire • RAPA and GeneActiv 7-day wrist-worn accelerometry • Smoking and alcohol • Education and occupation • Home ownership and number of cars • Geriatric depression scale • SF-36
Assessment of sarcopenia status	CARU	<ul style="list-style-type: none"> • SARC-F • Hand grip strength • Short physical performance battery: chair stand test, gait speed, balance tests • Segmental bioimpedance • DXA
Other clinical measurements	CARU	<ul style="list-style-type: none"> • Height and weight • Hip and waist circumference • Lying and standing blood pressure
Collection of skeletal muscle and other samples	CARU	<ul style="list-style-type: none"> • Vastus lateralis muscle biopsy • Blood samples (fasting) • Urine sample • Collection of stool sample kit

2

3 * With some conducted via videocall from September 2020 onwards.

4 CARU, Clinical Ageing Research Unit. DXA, dual-energy X-ray absorptiometry. MoCA,
 5 Montreal cognitive assessment. SF-36, Short Form 36 questionnaire. SMMSE, standardized
 6 mini-mental state examination. RAPA, rapid assessment of physical activity questionnaire.

1 **Table 2: Characteristics of the sample, by sex**

Characteristic	Males (n=37)	Females (n=43)	P-value*
Age (years)	65 [59, 73]	61 [56, 69]	0.248
Age category			0.594
45-54	5 (13.51)	8 (18.61)	
55-64	13 (35.14)	17 (39.53)	
65-74	14 (37.84)	12 (27.91)	
75-85	5 (13.51)	6 (13.95)	
Assessment of health, cognition, lifestyle and wellbeing			
No. long term conditions	1 [1,2]	2 [1,3]	0.548
No. medications	1 [0,2]	1 [1,4]	0.343
MoCA	27 [26, 28]	27 [25.5, 28]	0.656
RAPA 1 (aerobic)	6 [6, 7]	6 [6, 6.5]	0.132
RAPA 2 (strength and flexibility)	0 [0, 2]	1 [0, 3]	0.514
Daily MVPA (minutes)	32.06 [14.90, 45.85]	20.40 [7.07, 40.33]	0.064
Smoking history			0.393
Never	26 (70.27)	25 (58.14)	
Previous	11 (29.73)	17 (39.54)	
Current	0 (0.00)	1 (2.33)	
Accommodation			N/A
Home-owner	37 (100)	39 (90.7)	
Private / local authority tenant	0 (0.00)	4 (9.30)	
SF-36 general health score	59 [52, 65]	62 [58, 70]	0.046
SF-36 physical function score	100 [100, 100]	94.44 [88.89, 100]	< 0.001
Assessment of sarcopenia status and other clinical measurements			
SARC-F			N/A
0	34 (91.89)	32 (74.42)	
1	3 (8.11)	9 (20.93)	
2	0 (0.00)	0 (0.00)	
3	0 (0.00)	1 (2.33)	
4+	0 (0.00)	1 (2.33)	
Revised EWGSOP category			0.608
None	34 (91.89)	37 (86.05)	
Probable	3 (8.11)	4 (9.30)	
Confirmed	0 (0.00)	1 (2.33)	
Severe	0 (0.00)	1 (2.33)	
Maximum grip strength (kg)	42 [38, 46]	26 [21.5, 30.5]	Not tested
Maximum grip Z-score	0.27 [-0.31, 0.73]	0.02 [-0.49, 0.56]	0.757
Chair stand (5) (s)	11.15 [9.81, 13.38]	11.11 [9.6, 12.62]	0.655
ALMI from DEXA (kg/m ²)	8.29 [7.64, 8.90]	6.21 [5.73, 7.01]	Not tested
Gait speed (m/s)	1.25 [1.12, 1.32]	1.16 [1.01, 1.26]	0.035
BMI (kg/m ²)	26.40 [24.75, 28.04]	25.71 [22.96, 27.99]	0.341
BMI category			0.512
<25: Normal	11 (29.73)	18 (41.86)	
25-30: Overweight	20 (54.05)	20 (46.51)	
> 30: Obese	6 (16.22)	5 (11.63)	

1 Values shown are median [interquartile range] or count (%).
2
3 ALMI, appendicular lean mass index. BMI, body mass index. DXA, dual-energy X-ray
4 absorptiometry. EWGSOP, European Working Group on Sarcopenia in Older People. MoCA,
5 Montreal cognitive assessment. SF-36, Short Form 36 questionnaire. RAPA, rapid
6 assessment of physical activity questionnaire.
7
8 * Differences between males and females analysed using chi-squared tests in the case of
9 categorical variables and Wilcoxon rank-sum tests for continuous variables. RAPA and
10 SARC-F scores, and numbers of long-term conditions and medications have been treated as
11 categorical. Yates' continuity correction has been applied to the chi-squared test of SARC-F,
12 and continuity correction has also been applied in the Wilcoxon rank sum tests of maximum
13 grip strength, MOCA, SF-36 general health and physical function, gait speed and chair stand
14 because of ties in the data. Small numbers in some cells meant that a P-value could not
15 always be computed, as shown by N/A.